Condition: Myelodysplastic Syndromes · Sponsor: Syntrix Biosystems, Inc.
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
This description comes directly from the study's public registry record.
Aaron D Schuler, PhD · 253-833-8009 · aschuler@syntrixbio.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| AdventHealth Medical Group & Bone Marrow Transplant at Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04245397